Sugi Predict

Sugi Predict / Compounds / SCHEMBL12852

SCHEMBL12852

SCHEMBL12852

O=c1c(-c2ccccc2)c(Cn2cnc3c(Cl)ncnc32)oc2ccc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 3/20 0.40
▸ PDE10A Q9Y233 2/20 0.39
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ FGFR1 P11362 8/20 0.37
▸ FGFR4 P22455 8/20 0.37
▸ GABRP O00591 1/20 0.37
▸ GABRD O14764 1/20 0.37
▸ GABRA1 P14867 1/20 0.37
▸ GABRB1 P18505 1/20 0.37
▸ GABRG2 P18507 1/20 0.37
▸ GABRB3 P28472 1/20 0.37
▸ GABRA5 P31644 1/20 0.37
▸ GABRA3 P34903 1/20 0.37
▸ GABRA2 P47869 1/20 0.37
▸ GABRB2 P47870 1/20 0.37
▸ GABRA4 P48169 1/20 0.37
▸ GABRE P78334 1/20 0.37
▸ GABRA6 Q16445 1/20 0.37
▸ GABRG1 Q8N1C3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8786 0.89 MEN1 (0.41) HDAC6PDE10ACA1CA2FGFR1
SCHEMBL30670814 0.89 ADORA2A (0.48) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL7930 0.89 ADORA2A (0.48) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL30670884 0.81 NSD2 (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8093 0.81 NSD2 (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8148 0.80 ADORA2A (0.50) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL29651707 0.80 CYP11B1 (0.44) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL10907 0.80 CYP11B1 (0.44) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL11438 0.80 ALDH1A1 (0.38) PDE10AGABRPGABRDGABRA1GABRB1
SCHEMBL30013159 0.79 ADORA2A (0.49) ADORA2API4KAPI4K2BPI4K2API4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US claimed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US claimed
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 — — EP claimed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US claimed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 — — EP claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 — — EP claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) 2024-05-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 — — EP disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HDAC6 513/4885PDE10A 1270/4885CA1 4615/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HDAC6 513/4885PDE10A 1270/4885CA1 4615/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HDAC6 513/4885PDE10A 1270/4885CA1 4615/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A HDAC6 2411/4885PDE10A 1011/4885CA1 4543/4885
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS PDCD1, PDCD1LG2, CD274 HDAC6 433/4885PDE10A 3108/4885CA1 1456/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HDAC6 513/4885PDE10A 1270/4885CA1 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.